SV Life Sciences Raises Over US $570 Million for Fourth Fund, SV Life Sciences Fund IV.* Investor Base Broadened Significantly * Proven Track Record and Global Exposure Key Factors in Success BOSTON & SAN FRANCISCO San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden & LONDON -- SV Life Sciences (SVLS SVLS Sacramento Valley Live Steamers (Rancho Cordova, CA) ), formerly Schroder Ventures Life Sciences, today announced the final closing of SV Life Sciences Fund IV (SVLS IV) with total commitments of $572 million. The Fund was significantly oversubscribed Refers to connecting more users to a system than can be fully supported if all of them were using it at the same time. Networks and servers are almost always designed with some amount of oversubscription, counting on the fact that everybody does not need the service simultaneously. and SVLS decided to limit the final size. SVLS IV, SVLS's fourth international life sciences fund, brings the firm's total funds advised or managed to $1.6 billion, making it one of the largest venture capital investment groups dedicated to the life sciences sector. The diversified investment strategy of SVLS IV remains consistent with that of earlier funds. SVLS IV will be focused on providing start-up, early stage and expansion capital to private life sciences companies in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and Europe. SVLS IV will invest across a range of life sciences sectors, including biotechnology and pharmaceuticals, medical devices, healthcare services and healthcare information technology (IT). Anticipated investment size will typically be between $5 and $25 million. James Garvey, Chief Executive Officer and Managing Partner of SV Life Sciences in Boston, commented, "We experienced considerable success in the fundraising and were buoyed by the strength and proven track record of our team. In 2006 we had an exceptional year with sales of portfolio investments reaching over $2 billion as M&A activity in biotech and medical devices continued. This gave investors strong returns on their investment. We believe that our diversified investment strategy, across sectors, stages and geographies, will continue to provide broad investment opportunities for SVLS IV." "Part of the strategy for the SVLS IV fundraising was to broaden and diversify the investor base to ensure a good balance of commitments in the fund," Mr. Garvey continued. "As such, we are delighted to have attracted 32 high quality new investors to add to a strong group of dedicated investors from previous funds. This increased investor base spans globally with a concentration in the United States and Europe and includes more foundations, endowments, and family offices." Of the total commitments, approximately 60 percent came from the United States and 40 percent from Europe and Rest of World. Managing partners of the SVLS investment team include James Garvey, Kate Bingham, Lutz Giebel, Eugene Hill, David Milne David Milne may refer to:
Michael Bruce Ross (July 26, 1959 – May 13, 2005) was an American serial killer. Early life Ross was born in Putnam, Connecticut to Patricia Hilda Laine and Dan Graeme Ross. . They are a well established group of investment professionals whose complementary backgrounds and expertise spans the full range of the life sciences industry and balances investing expertise with deep operating experience at both private and publicly traded life sciences companies. Don Nelson, Chief Business Officer, led the fundraising for the Group. Venture capital funds Venture Capital Funds An investment fund that manages money from investors seeking private equity stakes in small and medium-size enterprises with strong growth potential. Notes: advised by SVLS have invested in the life sciences industry since the early 1980s and have backed over 100 life sciences companies globally. The existing funds, SV Life Sciences Funds I, II and III, were closed in 1994, 1999 and 2003 respectively, with total committed capital of over $800 million. SVLS also manages International Biotechnology Trust plc (Ticker: IBT (1) (Instructor Based Training) Training courses conducted by human teachers. (2) (Internet Based Training) Training courses provided via the Internet. ), a London Stock Exchange London Stock Exchange London marketplace for securities. It was formed in 1773 by a group of stockbrokers who had been doing business informally in local coffeehouses. listed investment trust with a market cap of $210 million. SV Life Sciences has US offices in Boston and the San Francisco Bay Area “Bay Area” redirects here. For other uses, see Bay Area (disambiguation). The San Francisco Bay Area, colloquially known as the Bay Area or The Bay , and a European office in London. For additional information on SVLS, please visit www.svlsa.com. Notes to Editors: SV Life Sciences (SVLS) was established in 1993, in London and Boston, to take advantage of the global nature of the life sciences opportunity and to enable active deal leadership in the key markets. The SVLS team is composed of 28 professionals with extensive life sciences investment, strategic, operational, scientific and clinical experience. In addition to SV Life Sciences Fund IV, SVLS advises and/or manages three other private equity funds, SVLS Funds I, II and III. These funds provide start-up, early stage and expansion capital to life sciences companies in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. and Europe. Approximately half of the investments have been in the biotech sector with the remaining half split equally between the medical device and healthcare service sectors. This broad sector, stage and regional diversification and capability, which will be continued in SVLS Fund IV, is relatively unique when compared to other peer life sciences focused venture capital funds. Further information is available at www.svlsa.com. The Group also has a capability in the public markets with a dedicated team that manages International Biotechnology Trust plc, a publicly quoted investment trust listed on the London Stock Exchange (Ticker: IBT), with a total net asset value of approximately $210 million. IBT primarily invests in high growth, development stage public life sciences companies with an emphasis on small cap US biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. . Further information is available at www.internationalbiotrust.com. Examples of successful exits (greater than 5 times capital returned) include Chiroscience, Eyetech Pharmaceuticals, GelTex Pharmaceuticals, GlycoFi, Kinetix Pharmaceuticals, LaserVision, LeukoSite, PowerMed, Rinat Neuroscience neu·ro·sci·ence n. Any of the sciences, such as neuroanatomy and neurobiology, that deal with the nervous system. neuroscience the embryology, anatomy, physiology, biochemistry and pharmacology of the nervous system. , Shire Shire or Shiré (both: shē`rā), river, c.250 mi (400 km) long, flowing from the southern end of Lake Nyasa, Malawi, SE Africa, to the Zambezi River in central Mozambique. It is navigable to Nsanje. Pharmaceuticals, (Ticker: SHP, SVLS was the founding investor in 1987) and Triangle Pharmaceuticals. For a complete list of current investments please see the SVLSA website at www.svlsa.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion